Atherosclerosis
Volume 205, Issue 1 , Pages 197-201 , July 2009

Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels

  • Seiko Otokozawa

      Affiliations

    • Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, United States
    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, United States
    • ,
  • Masumi Ai

      Affiliations

    • Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, United States
    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, United States
    • ,
  • Thomas Van Himbergen

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, United States
    • ,
  • Bela F. Asztalos

      Affiliations

    • Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, United States
    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, United States
    • ,
  • Akira Tanaka

      Affiliations

    • Nutrition Clinic, Kagawa Nutrition University, Tokyo, Japan
    • ,
  • Evan A. Stein

      Affiliations

    • Metabolic and Atherosclerosis Research Center, Cincinnati, OH, United States
    • ,
  • Peter H. Jones

      Affiliations

    • Baylor College of Medicine, Houston, TX, United States
    • ,
  • Ernst J. Schaefer

      Affiliations

    • Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, United States
    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, United States
    • Corresponding Author InformationCorresponding author at: Tufts University, 711 Washington Street, Boston, MA 02111, USA. Tel.: +1 617 556 3100; fax: +1 617 556 3103.

Received 23 May 2008 ,Revised 30 October 2008 ,Accepted 4 November 2008.

References 

  1. STELLAR Study GroupJones PH, Davidson MH, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160
  2. Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study GroupJones PH, Hunninghake DB, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia additional results from the STELLAR trial. Clin Ther. 2004;26:1388–1488
  3. Asztalos BF, LeMaulf F, Dallal GE, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high density lipoproteins. Am J Cardiol. 2007;99:681–685
  4. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181–2187
  5. Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–2191
  6. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:847–852
  7. Ai M, Otokozawa S, Asztalos BF, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low density lipoprotein cholesterol levels. Am J Cardiol. 2008;101:315–318
  8. Sugiuchi H, Irie T, Uji Y, et al. Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer α-cyclodextrin sulfate. Clin Chem. 1998;44:522–531
  9. Sugiuchi H, Uji Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995;41:717–723
  10. Miyauchu K, Kayahara N, Ishigami M, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007;53:2128–2135
  11. Miyauchi K, Kuwata H, Sugiuchi H, Irie T. Development of a direct remnant lipoprotein cholesterol assay using detergent. Jap J Clin Chem. 2005;34:325
  12. Nakada Y, Kurosawa H, Tohyama J, Inoue Y, Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease—evaluation utilizing a newly developed remnant assay, remnant lipoprotein cholesterol homogeneous assay (RemL-C). J Atheroscler Thromb. 2007;14:56–64
  13. Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta. 2005;351:115–120
  14. Lamon-Fava S, Diffenderfer MR, Barrett PHR, et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res. 2007;48:1746–1753
  15. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J. Lipid Res. 1988;29:925-936.1
  16. Schaefer EJ, Audelin MC, McNamara JR, et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol. 2001;88:1129–1133
  17. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001;154:229–236
  18. Schaefer EJ, McNamara JR, Shah PK, et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care. 2002;25:989–994
  19. Siegel RD, Cupples A, Schaefer EJ, Wilson PWF. Lipoproteins, apolipoproteins, and low density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism. 1996;45:1267–1272
  20. Campos E, Kotite L, Blanche P, et al. Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human plasma. J Lipid Res. 2002;43:365–374
  21. Schaefer EJ, McNamara JR, Tayler T, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol. 2002;90:689–696
  22. Schaefer EJ, McNamara JR, Tayler T, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol. 2004;93:31–39
  23. Castro Cabezas M, Erkelens DW, Kock LA, De Bruin TW. Postprandial apolipoprotein B100 and apoB48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest. 1994;10:669–678
  24. Battula SB, Fitzsimmons O, Moreno S, et al. Postprandial apolipoprotein B-48- and apoB-100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism. Metabolism. 2000;49:1049–1054
  25. Dane-Stewart CA, Watts GF, Pal S, et al. Effect of atorvastatin on apolipoprotein B-48 metabolism and low density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 2003;52:1279–1286
  26. Verseyden C, Meijssen S, Cabezas MC. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B-48 and B-100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2004;89:5021–5029
  27. Hogue JC, Lamarche B, Deshaies Y, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and apoB-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008;57:246–254
  28. Campos H, Khoo C, Sacks FM. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic subjects. Atherosclerosis. 2005;181:345–351J Lipid Res 43: 365; 2002

PII: S0021-9150(08)00778-8

doi: 10.1016/j.atherosclerosis.2008.11.001

Atherosclerosis
Volume 205, Issue 1 , Pages 197-201 , July 2009

Article Tools

* Image Usage & Resolution